The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer

Masatsune Shibutani*, Kiyoshi Maeda, Hisashi Nagahara, Yasuhiro Iseki, Kosei Hirakawa and Masaichi Ohira

Abstract
Inflammation has been reported to play an important role in cancer progression and various inflammatory markers have been reported to be useful prognostic markers. The aim of this retrospective study was to evaluate the significance of the C-reactive protein to albumin (CRP/ALB) ratio in colorectal cancer patients who received palliative chemotherapy. We performed a retrospective review of 99 patients who underwent palliative chemotherapy for unresectable colorectal cancer between 2005 and 2010. The cutoff value of the CRP/ALB ratio was determined based on a receiver operating characteristics curve analysis. The relationship between the CRP/ALB ratio and survival was assessed. The cutoff value for the CRP/ALB ratio was 0.183. The high pretreatment CRP/ALB ratio group showed significantly worse overall survival. Patients with a high pretreatment CRP/ALB ratio and in whom the CRP/ALB ratio normalized after chemotherapy tended to have better overall survival than those in whom both the pretreatment and posttreatment CRP/ALB ratios were high. The CRP/ALB ratio is a useful marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer.

Keywords: Colorectal cancer, Prognosis, Unresectable, C-reactive protein to albumin ratio, Chemotherapeutic effectiveness

Background
Colorectal cancer (CRC) is one of the most common causes of cancer-related death worldwide (Edwards et al. 2014). Unresectable metastasis is one of the most important prognostic factors for patients with CRC (Shibutani et al. 2015b). In spite of advances in chemotherapy, which include new cytotoxic and molecular targeted therapies, the prognosis of patients with unresectable metastatic CRC remains poor, with a median survival time of approximately 30 months (Heinemann et al. 2014; Grothey et al. 2008). The assessment of prognostic factors is therefore important for the management of unresectable metastatic CRC patients.

It is well known that there is a close relationship between inflammation and cancer progression (Mantovani et al. 2008; Balkwill and Mantovani 2001) and some inflammatory markers have been investigated as prognostic factors in CRC (Shibutani et al. 2013, 2014; McMillan et al. 2007; Maeda et al. 2015). The C-reactive protein-to-albumin (CRP/ALB) ratio has been reported to be a more accurate prognostic value in patients with various malignancies than the modified Glasgow prognostic score (mGPS) (Kinoshita et al. 2015; Xu et al. 2015), which is also calculated from the serum CRP and ALB concentration, and we previously reported on the prognostic significance of the CRP/ALB ratio in patients
with CRC who underwent curative surgery (Shibutani et al. 2016). However, aside from our report, there have only been a few reports regarding the prognostic significance of the CRP/ALB ratio in patients with CRC (Ishizuka et al. 2016). Moreover, to the best of our knowledge, there are no published studies regarding the prognostic significance of the CRP/ALB ratio in patients with unresectable metastatic CRC. Therefore, we applied this marker to patients with unresectable metastatic CRC and compared the usefulness of the CRP/ALB ratio with that of other inflammatory markers for predicting and monitoring the therapeutic outcome.

The aim of the present study is to evaluate the significance of the CRP/ALB ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic CRC.

Methods
Patients
We retrospectively reviewed a database of 99 patients who underwent palliative combination chemotherapy for unresectable metastatic colorectal cancer at the Department of Surgical Oncology of Osaka City University between 2005 and 2010.

The patient characteristics are listed in Table 1. The patient population consisted of 57 males and 42 females, with a median age of 63 years (range 27–86). Forty of the patients had metachronous unresectable cancer; 59 had synchronous unresectable cancer. Fifty-four patients had single organ metastasis and 45 patients multiple organs affected by metastases. All of the patients underwent combination chemotherapy with oxaliplatin, or irinotecan plus 5-fluorouracil/leucovorin, or a prodrug of 5-fluorouracil as a first-line chemotherapy. Regimens considered to have the same efficacy were used for all of the patients in this study (Cassidy et al. 2008; Tournigand et al. 2004; Yamada et al. 2013). Sixty-five patients received 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX), 21 patients received capecitabine + oxaliplatin (CapeOX), nine patients received 5-fluorouracil + leucovorin + irinotecan (FOLFIRI) and four patients received S-1 + oxaliplatin (SOX). Sixty-nine patients underwent chemotherapy combined with molecular targeted therapy. The median follow-up period for the surviving patients was 20.8 months (range 2.6–73.2 months). Sixty-three patients died during the follow-up period.

Evaluation
Response evaluations were performed every eight weeks. A variation of approximately one week was regarded as an allowable error. All of the patients were followed up with a physical examination, blood tests (these included measurements of tumor marker levels such as carcinoembryonic antigen [CEA]), computed tomography and ultrasonography.

The pretreatment blood samples were obtained within one week before the initiation of chemotherapy; the post-treatment blood samples were obtained eight weeks after

| Table 1 The patients’ characteristics |
|--------------------------------------|
| Age (years)                          |
| Median (range)                       | 63 (27–86) |
| Gender                               |
| Male                                 | 57         |
| Female                               | 42         |
| Location of primary tumor            |
| Colon                                | 57         |
| Rectum                               | 42         |
| Histological type                    |
| Well, moderately                     | 78         |
| Poorly, mucinous                     | 12         |
| Unknown                              | 9          |
| Detection of unresectable tumor      |
| Synchronous                          | 59         |
| Metachronous                         | 40         |
| The number of organs affected by metastasis |
| One organ                            | 54         |
| Multiple organs                      | 45         |
| First-line chemotherapy regimen      |
| FOLFOX                                | 65         |
| CapeOX                                | 21         |
| FOLFIRI                               | 9          |
| SOX                                   | 4          |
| Molecular targeted therapy           |
| Bevacizumab                           | 50         |
| Cetuximab                             | 15         |
| Panitumumab                           | 4          |
| None                                  | 30         |
| The pretreatment C-reactive protein level |
| Median (range)                       | 0.32 (0.02–13.46) |
| The pretreatment albumin level       |
| Median (range)                       | 3.9 (2.4–4.7)  |
| The pretreatment CRP/ALB ratio       |
| Median (range)                       | 0.084 (0.004–5.608) |
| The pretreatment NLR                  |
| Median (range)                       | 2.788 (0.580–16.306) |
| mGPS                                  |
| 0                                    | 69         |
| 1                                    | 21         |
| 2                                    | 9          |

FOLFOX 5-fluorouracil + leucovorin + oxaliplatin, CapeOX capecitabine + oxaliplatin, FOLFIRI 5-fluorouracil + leucovorin + irinotecan, SOX S-1 + oxaliplatin, CRP/ALB ratio C-reactive protein to albumin ratio, NLR neutrophil to lymphocyte ratio, mGPS modified Glasgow prognostic score
the initiation of chemotherapy. The serum CRP and ALB concentrations were measured using a chemiluminescent immunoassay (Wako, Osaka, Japan) according to the manufacturer’s protocol. The differential white blood cell count was analyzed using an XE-5000 hematology analyzer (Sysmex, Kobe, Japan) based on the manufacturer’s protocol. The CRP/ALB ratio was calculated from the preoperative blood samples by dividing the serum CRP level by the serum ALB level. The mGPS was defined according to the methods of a previous report (Petrelli et al. 2015), using the combination of the serum CRP and ALB levels: patients with a CRP level of <1.0 mg/dl were allocated a score of 0; those in whom the CRP and ALB levels were ≥1.0 mg/dl and ≥3.5 g/dl, respectively, were allocated a score of 1; and those in whom the CRP and ALB levels were ≥1.0 mg/dl and ALB < 3.5 g/dl, respectively, were allocated a score of 2. The neutrophil to lymphocyte ratio (NLR) was calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count.

Statistical analysis
The significance of the correlations between the pretreatment CRP/ALB ratio and the clinicopathological characteristics were analyzed using the χ² test. The duration of survival was calculated according to the Kaplan–Meier method. Differences in the survival curves were assessed using the log-rank test. A multivariate analysis was performed according to the Cox proportional hazard model. All of the statistical analyses were conducted using the SPSS software package for Windows (SPSS Japan, Tokyo, Japan). p values of <0.05 were considered to indicate statistical significance.

Ethical consideration
This research was conformed to the provisions of the Declaration of Helsinki in 1975. All patients were informed of the investigational nature of this study and provided written informed consent. This retrospective study was approved by the ethics committee of Osaka City University.

Results
Classifications according to the pretreatment inflammatory markers
We used the CRP/ALB ratio, which was a continuous variable, as the test variable and the 24-month survival (median survival time: 24 months) as the state variable. When we investigated the cut-off value for the CRP/ALB ratio using the receiver operating characteristic (ROC) curve, we found that the appropriate cut-off value for the CRP/ALB ratio was 0.183 (sensitivity: 53.5 %; specificity: 72.1 %) (Fig. 1a). We therefore set 0.183 as the cut-off value and the patients were classified into the high-CRP/ALB ratio (n = 36) and low-CRP/ALB ratio (n = 63) groups. Using the ROC curve in the same manner, we set the cut-off value for the NLR at 3.0 (sensitivity: 65.0 %, specificity: 78.0 %) (Fig. 1b). In accordance with the findings of previous reports, the study population was classified into the patients with an mGPS of 0 or 1 and the
patients with an mGPS of 2 (Sugimoto et al. 2012; Furu-
kawa et al. 2012).

The correlations between the pretreatment CRP/ALB ratio and the clinicopathological factors
The correlations between the pretreatment CRP/ALB ratio and the clinicopathological factors are shown in Table 2. The pretreatment CRP/ALB ratio had no significant relationships with any of the clinicopathological factors except for the pretreatment mGPS and NLR.

The survival analysis based on the pretreatment inflammatory markers
The overall survival rate was significantly worse in the high pretreatment CRP/ALB ratio group than in the low pretreatment CRP/ALB ratio group (p = 0.0009) (Fig. 2a). The overall survival rate was significantly worse in patients with an mGPS of 2 than in those with an mGPS of 0 or 1 (p = 0.0450) (Fig. 2b). The overall survival rate was significantly worse in the high neutrophil to lymphocyte ratio group than in the low neutrophil to lymphocyte group (p < 0.0001) (Fig. 2c).

The survival analysis based on the pretreatment CRP/ALB ratio, limited to the patients with an mGPS of 0 or 1
We then performed a sub-analysis limited to patients with an mGPS of 0 or 1. Among these patients, the overall survival rate was significantly worse in the high-CRP/ALB ratio group than in the low-CRP/ALB ratio group (p = 0.0048) (Fig. 2d).

The prognostic factors influencing long-term survival
The correlations between overall survival and the various clinicopathological factors are shown in Table 3. According to the results of a univariate analysis, overall survival showed significant relationships with the number of organs affected by metastasis (p = 0.024), the use of a molecular targeted therapy (p = 0.001), the pretreatment CRP/ALB ratio (p = 0.001) and the pretreatment NLR (p = 0.001). A multivariate analysis indicated that the use of a molecular targeted therapy (hazard ratio 0.341; 95 % confidence interval 0.186–0.626; p = 0.001), the pretreatment CRP/ALB ratio (hazard ratio 1.866; 95 % confidence interval 1.057–3.295; p = 0.031) and the pretreatment NLR (hazard ratio 2.706; 95 % confidence interval 1.483–4.939; p = 0.001) were independent prognostic factors for overall survival.

The correlation between the normalization of the CRP/ALB ratio at eight weeks after chemotherapy and survival
We evaluated the prognostic significance of the normalization of the CRP/ALB ratio at eight weeks after the initiation of chemotherapy. We categorized the patients into three groups according to their pretreatment and posttreatment CRP/ALB ratio values. Patients with a low pretreatment CRP/ALB ratio were categorized into group A. Patients with a high pretreatment CRP/ALB ratio and a normalized CRP/ALB ratio at eight weeks after the initiation of chemotherapy were categorized into group B. Patients with high pretreatment and posttreatment CRP/ALB ratio values were categorized into group C. The patients in group B tended to exhibit a better prognosis than those in group C (p = 0.0641) (Fig. 3).

Table 2 The correlations between the pretreatment CRP/ALB ratio and the clinicopathological factors

| Pretreatment CRP/ALB ratio | Low | High | p value |
|---------------------------|-----|------|---------|
| Gender Male                | 36  | 21   | 1.000   |
| Female                    | 27  | 15   |         |
| Age <65                    | 34  | 19   |         |
| Age ≥65                   | 29  | 17   |         |
| Location of primary tumor  | Colon | 36 | 21 | 1.000 |
| Location of primary tumor  | Rectum | 27 | 15 |         |
| Detection of unresectable tumor Synchronous | 34 | 25 | 0.143 |
| Detection of unresectable tumor Metachronous | 29 | 11 |         |
| Histological type Well, moderately | 51 | 27 | 0.744 |
| Histological type Poorly, mucinous | 9 | 3 |         |
| Peritoneal dissemination Negative | 47 | 33 | 0.061 |
| Peritoneal dissemination Positive | 16 | 3 |         |
| The number of organs affected by metastasis One organ | 36 | 18 | 0.534 |
| The number of organs affected by metastasis Multiple organs | 27 | 18 |         |
| Pretreatment CEA (ng/ml) ≤5 | 9 | 4 | 0.765 |
| Pretreatment CEA (ng/ml) >5 | 53 | 31 |         |
| Molecular targeted therapy No | 17 | 12 | 0.503 |
| Molecular targeted therapy Yes | 46 | 24 |         |
| Pretreatment mGPS 0 | 63 | 6 |         |
| Pretreatment mGPS 1 | 0 | 21 |         |
| Pretreatment mGPS 2 | 0 | 9 | <0.001 |
| Pretreatment NLR <3 | 41 | 13 | 0.003 |
| Pretreatment NLR ≥3 | 18 | 22 |         |

CRP/ALB ratio C-reactive protein to albumin ratio, CEA carcinoembryonic antigen, mGPS modified Glasgow prognostic score, NLR neutrophil to lymphocyte ratio
Fig. 2 The Kaplan–Meier survival curves for overall survival. 

a The overall survival rate was significantly worse in the high-C-reactive protein to albumin (CRP/ALB) ratio group than in the low-CRP/ALB ratio group ($p = 0.0009$).

b The overall survival rate was significantly worse in patients with a modified Glasgow prognostic score (mGPS) of 2 than in those with an mGPS of 0 or 1 ($p = 0.0450$).

c The overall survival rate was significantly worse in the high neutrophil to lymphocyte ratio (NLR) group than in the low NLR group ($p < 0.0001$).

d Kaplan–Meier survival curves for overall survival in an analysis limited to the patients with a modified Glasgow prognostic score (mGPS) of 0 or 1. The overall survival rate was significantly worse in the high-C-reactive protein to albumin (CRP/ALB) ratio group than in the low-CRP/ALB ratio group ($p = 0.0048$).

### Table 3 The correlations between overall survival and various clinicopathological factors

| Factor                                                                 | Univariate analysis | Multivariate analysis |
|-----------------------------------------------------------------------|---------------------|-----------------------|
|                                                                       | Hazard ratio  | 95 % CI | p value | Hazard ratio  | 95 % CI | p value |
| Gender (female vs. male)                                              | 1.473          | 0.895–2.423 | 0.128  | 1.099         | 0.595–2.030 | 0.763  |
| Age ($\geq 65$ vs. <65)                                               | 1.492          | 0.907–2.454 | 0.115  | 1.115         | 0.622–1.997 | 0.715  |
| Location of primary tumor (colon vs. rectum)                          | 1.273          | 0.769–2.108 | 0.348  | 1.124         | 0.609–2.075 | 0.708  |
| Detection of unresectable tumor (synchronous vs. metachronous)        | 1.595          | 0.946–2.688 | 0.080  | 1.099         | 0.595–2.030 | 0.763  |
| Histological type (poorly, mucinous vs. well, moderately)             | 1.417          | 0.688–2.916 | 0.344  | 1.124         | 0.609–2.075 | 0.708  |
| Peritoneal dissemination (yes vs. no)                                 | 1.124          | 0.609–2.075 | 0.708  | 1.124         | 0.609–2.075 | 0.708  |
| The number of organs affected by metastasis ($\geq 2$ vs. <2)         | 1.775          | 1.078–2.923 | 0.024  | 1.115         | 0.622–1.997 | 0.715  |
| Pretreatment CEA (>$5$ ng/ml vs. $\leq 5$ ng/ml)                     | 2.193          | 0.940–5.113 | 0.069  | 1.370         | 0.526–3.571 | 0.520  |
| Molecular targeted therapy (yes vs. no)                               | 0.391          | 0.227–0.676 | 0.001  | 0.341         | 0.186–0.626 | 0.001  |
| Pretreatment CRP/ALB ratio ($>0.183$ vs. $\leq 0.183$)               | 2.301          | 1.390–3.807 | 0.001  | 1.866         | 1.057–3.295 | 0.031  |
| Pretreatment NLR ($>3$ vs. $\leq 3$)                                 | 3.777          | 2.191–6.511 | <0.001 | 2.706         | 1.483–4.939 | 0.001  |

*CEA* carcinoembryonic antigen, *CRP/ALB ratio* C-reactive protein to albumin ratio, *NLR* neutrophil to lymphocyte ratio
Discussion

There have been various studies on the close relationship between inflammation and cancer since the relationship was first reported by Virchow in 1863 (Mantovani et al. 2008; Balkwill and Mantovani 2001). Recently, inflammation has been widely recognized to contribute to cancer progression and various inflammatory markers, such as the NLR, CRP, GPS and mGPS have been reported to be correlated with the survival of patients with CRC (Shibutani et al. 2013, 2014; McMillan et al. 2007; Sugimoto et al. 2012; Furukawa et al. 2012).

Inflammation induces an increase in the levels of cytokines, which play an important role in tumor proliferation, progression, invasion and metastasis, as well as in resistance to chemotherapy (Colotta et al. 2009; Coussens and Werb 2002; Heikkilä et al. 2007). Therefore, inflammatory markers are considered to reflect the momentum of cancer growth. Furthermore, the levels of systemic inflammatory markers have been reported to correlate with tumor volume (Shibutani et al. 2013, 2014; McMillan et al. 2007; Sugimoto et al. 2012; Furukawa et al. 2012).

Inflammation induces an increase in the levels of cytokines, which play an important role in tumor proliferation, progression, invasion and metastasis, as well as in resistance to chemotherapy (Colotta et al. 2009; Coussens and Werb 2002; Heikkilä et al. 2007). Therefore, inflammatory markers are considered to reflect the momentum of cancer growth. Furthermore, the levels of systemic inflammatory markers have been reported to correlate with tumor volume (Shibutani et al. 2013, 2014; McMillan et al. 2007; Sugimoto et al. 2012; Furukawa et al. 2012). In this way, inflammatory markers are considered to be useful for predicting and monitoring the therapeutic outcome in patients with malignancies.

The CRP/ALB ratio was primarily investigated for the purpose of predicting mortality in patients with sepsis. The CRP/ALB ratio was also applied to predicting the prognosis of patients with cancer and its usefulness has been reported in patients with various cancers, such as hepatocellular carcinoma, esophageal cancer and lung cancer (Kinoshita et al. 2015; Xu et al. 2015; Zhou et al. 2015). In previous reports, the CRP/ALB ratio was shown to have an outstanding prognostic value in comparison to other established inflammation-based prognostic markers (Kinoshita et al. 2015; Xu et al. 2015). Although the area under curve (AUC) value of the CRP/ALB ratio was lower than that of the NLR, the CRP/ALB ratio was shown to be a valuable marker and was thus found to be sufficient for predicting survival in the present study.

As Casadei Gardini reported, the serum CRP concentration alone is also significantly correlated with the survival (Casadei Gardini et al. 2016). We came to the same conclusion based on the findings in our previous study (Shibutani et al. 2015b). However, Ranzani reported that the CRP/ALB ratio was more closely correlated with survival than the CRP values alone (Ranzani et al. 2013). By combining the CRP and albumin values, which have both been reported to be independent prognostic factors for various types of cancer, the CRP/ALB ratio is believed to be a more useful marker.

The mGPS, which has been reported to be a useful prognostic marker in patients with CRC, is similar to the CRP/ALB ratio, as both results can be calculated from the serum CRP and albumin concentration. However, the majority of the patients are classified with an mGPS of 0 or 1, which is associated with a better prognosis (Sugimoto et al. 2012; Furukawa et al. 2012). In the present study, approximately 90 % of the patients were found to have an mGPS of 0 or 1. For this reason, most patients could not be classified by the mGPS. On the other hand, the patients who had an mGPS of 0 or 1 could be classified into two groups according to their CRP/ALB ratios and significant differences were observed between the two groups. It can therefore be said that the CRP/ALB ratio is a more accurate prognostic marker than the mGPS.

Moreover, the normalization of the CRP/ALB ratio at eight weeks after the initiation of chemotherapy tended to be correlated with an improvement in overall survival. Based on this result, the CRP/ALB ratio is considered to be a useful marker for monitoring the effectiveness of chemotherapy as well as for predicting survival. On the other hand, it has been reported that there is no relationship between the normalization of the NLR and survival, because the value is easily affected by chemotherapy-induced myelosuppression (Shibutani et al. 2015a). Therefore, the CRP/ALB ratio was believed to be superior to the NLR for evaluating the efficacy of chemotherapy. Although previous studies have primarily focused on the prognostic significance of the pretreatment CRP/ALB ratio, in the present study, the CRP/ALB ratio was revealed to be a useful marker for monitoring the effectiveness of chemotherapy as well as for predicting survival.

Although we set 0.183 as the CRP/ALB ratio cut-off value according to the results of the ROC analysis, other
studies have used various cut-off values. Because the inflammatory markers were reported to be associated with the degree of tumor progression, such as the TNM stage (Shibutani et al. 2013; Xu et al. 2015; Ishizuka et al. 2016), the appropriate cut-off value may change according to the background characteristics of the patients.

The present study is associated with some possible limitations. First, we evaluated a relatively small number of patients and the study design was retrospective in nature. Second, comorbidities that may have affected systemic inflammation and the serum albumin concentration (such as infection, ischemia, acute coronary disease, liver cirrhosis, and nephrotic syndrome) were not taken into consideration. A large prospective study should therefore be performed to confirm our findings.

Conclusions
The CRP/ALB ratio is a useful marker not only for predicting survival, but also for monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer who receive palliative chemotherapy.

Abbreviations
CRP: C-reactive protein; ALB: albumin; mGPS: modified Glasgow prognostic score; FOLFOX: 5-fluorouracil + oxaliplatin; CapeOX: capecitabine + oxaliplatin; CapeCE: capecitabine + capecitabine + oxaliplatin; FOLFIRI: 5-fluorouracil + leucovorin + irinotecan; SOX: S-1 + oxaliplatin; CEA: carcinoembryonic antigen; NLR: neutrophil to lymphocyte ratio; ROC: receiver operating characteristic.

Authors’ contributions
MS and KM designed the study, performed the statistical analysis and drafted the manuscript. HN and YI collected the clinical data. KH designed the study and performed the statistical analysis and drafted the manuscript. MO critically reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This research received no specific grants from any funding agency in the public, commercial or not-for-profit sectors. We thank Brian Quinn who provided medical writing services on behalf of JMC, Ltd.

Competing interests
The authors declare that they have no competing interests.

Received: 8 March 2016 Accepted: 12 October 2016

Published online: 18 October 2016

References
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
Casadei Gardini A, Carloni S, Scarpi E, Maltoni P, Dorizzi RM, Passardi A et al (2016) Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACA trial. Oncotarget 7:10193–10202
Cassidy J, Clarke S, Diaz-Rubio E, Schelfhauter W, Figer A, Wong R et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Edwards BK, Noone AM, Mariotto AB, Simard EP, Bocce FP, Henley SJ et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290–1314
Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuysa Y et al (2012) The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett 4:324–328
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326–5334
Heikkila K, Ebrahim S, Lavelio DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Commun Health 61:824–833
Heinemann V, von Weikersthal LF, Deckter T, Kiani A, Vehling-Kaiser U, Al-Batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075
Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K (2016) Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol 23:900–907
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K et al (2015) The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22:803–810
Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y et al (2015) Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol 7:111–117
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
McMillan DC, Crozier JE, Cann A, Anderson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886
Petrelli P, Banni S, Coinu A, Bertocci P, Borgonovo K, Cabiddu M et al (2015) The Modified Glasgow prognostic score and survival in colorectal cancer: a pooled analysis of the literature. Rev Recent Clin Trials 10:135–141
Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M (2013) C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One 8:e59321
Shibutani M, Maeda K, Nagahara H, Noda E, Ohhata H, Nishiguchi Y et al (2013) A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 33:3291–3294
Shibutani M, Maeda K, Nagahara H, Ohhata H, Sugano K, Ikeya T et al (2014) Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer. Hepatogastroenterology 61:2236–2240
Shibutani M, Maeda K, Nagahara H, Ohhata H, Sakurai K, Yamazoe A et al (2015a) Significance of markers of systemic inflammation for predicting survival and chemotherapeutic outcomes and monitoring tumor progression in patients with unresectable metastatic colorectal cancer. Anticancer Res 35:5037–5046
Shibutani M, Maeda K, Nagahara H, Noda E, Ohhata H, Nishiguchi Y, Sakurai K, Hirakawa K (2015b) Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surg Today 45:315–321
Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K (2016) Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res 36:1005–1001
Sugimoto K, Komiya H, Kojima Y, Goto M, Tomiki Y, Sakamoto K (2012) Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg 29:503–539
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

Xu XL, Yu HQ, Hu W, Song Q, Mao WM (2015) A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One 10:e0138657

Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278–1286

Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T et al (2015) Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 5:10481